NCT05898048

CMV Reactivation in Acute Necrotizing Pancreatitis

Completed Last updated 24 April 2025

What this trial tests

trial in Acute Necrotizing Pancreatitis in 41 participants. Completed in 30 November 2024.

Timeline

5 June 2023

Primary endpoint
30 November 2024

30 November 2024

Quick facts

Lead sponsor	Sanjay Gandhi Postgraduate Institute of Medical Sciences
Status	Completed
Study type	OBSERVATIONAL
Enrollment	41
Start date	5 June 2023
Primary completion	30 November 2024
Estimated completion	30 November 2024
Sites	1 location across India

Conditions studied

• Acute Necrotizing Pancreatitis — all drugs for Acute Necrotizing Pancreatitis →

Sponsor

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Who can join

Adults 18 to 80, any sex, with Acute Necrotizing Pancreatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with the diagnosis of acute necrotizing pancreatitis (ANP) present with a wide spectrum of severity. These patients frequently require intensive care management. According to the revised Atlanta classification (2012), acute pancreatitis is divided into distinct subtypes, based on the presence or absence of necrosis. The mortality rates for sterile necrosis though comparatively low (5%-10%), but superinfection of the necrotic pancreas and peri-pancreatic tissue/ fluid collections increases the mortality rate considerably (up to one-third). The most common organisms isolated from the infected pancreatic necrosum are gram-negative bacteria mainly Escherichia coli and Klebsiella pneumoniae followed by gram-positive bacteria; however, with the increased use of antibiotic therapies in the ICU, the incidence of pancreatic fungal infections is also on a rise. Traditionally, critically ill patients have been considered immunocompetent but the immunomodulatory effects of sepsis may lead to reactivation of dormant viral infections. In recent years, Cytomegalovirus (CMV) reactivation in critically ill patients has been recognized with as high as 71% incidence with associated higher mortality, organ failure rates, duration of mechanical ventilation, nosocomial infections, and ICU length of stay. CMV reactivation had been studied in various cohorts in the ICU population, such as acute respiratory distress syndrome (ARDS) and septic shock exhibiting their impact on mortality. However, currently, no study is available investigating the role of CMV reactivation in patients with acute necrotizing pancreatitis. Therefore, the investigators aimed to study the prevalence of CMV reactivation and its viral load kinetics in critically ill patients with acute necrotizing pancreatitis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. ESICM LIVES 2024. Barcelona, Spain. 5–9 October 2024.
   · 2024 · cited 1× · PMID 39361093 · DOI 10.1186/s40635-024-00658-z
2. Cytomegalovirus Reactivation in Critically Ill Patients With Acute Necrotizing Pancreatitis.
   Singh U, Gurjar M, Garg A, Mohindra S, et al · · 2025 · PMID 40838259 · DOI 10.1093/ofid/ofaf438